Boris Decourt, Ph.D., Joins Cleveland Clinic Nevada

By January 11, 2019 Press Release, Recognition

Boris Decourt, Ph.D., Joins Cleveland Clinic Nevada to Lead Center’s First Translational Neurodegeneration Research Lab

Neurobiologist will enhance research capabilities with the addition of translational research to help create new therapies and improve clinical outcomes

Cleveland Clinic Nevada welcomes Boris Decourt, Ph.D., as assistant staff to spearhead its first Translational Neurodegeneration Research Lab. 

Decourt, a neurobiologist, brings 15 years of experience to the center’s robust research program, most recently serving as an assistant research professor at Arizona State University. Through his work in fundamental science – a branch of science that provides a foundation of knowledge essential for applying discoveries to patient care – Cleveland Clinic Nevada will now be able to broaden the scope of its clinical trials program.

The addition of this new research capability cultivates an environment for translational research, which builds on basic scientific research to create new therapies, medical procedures, or diagnostics. This will allow physicians to readily apply what’s learned in the research lab to clinical care, helping to improve overall patient outcomes.

 “We are thrilled to add a talent like Dr. Decourt to our team, which allows us to elevate our research capabilities through our inaugural Translational Neurodegeneration Research Lab right here in Las Vegas,” said Marwan Sabbagh, M.D., FAAN, CCRI, director of the Camille and Larry Ruvo Endowed Chair for Brain Health at the Lou Ruvo Center for Brain Health. “Cleveland Clinic remains committed to innovation and Dr. Decourt’s expertise and ability to conduct fundamental research will be instrumental in exploring new treatment options for Alzheimer’s disease.”                                                                  

Decourt received his doctorate of philosophy in neuroscience and pharmacology from The University of Bordeaux in France. He has since conducted nearly 10 influential research projects, specifically targeting early treatment options for Alzheimer’s disease in association with Arizona Alzheimer’s Research Consortium and an Alzheimer’s Association Research Fellowship, among others. In his new role, he will be working in conjunction with physicians on a variety of research projects out of the Translational Neurodegeneration Research Lab located at Roseman University.

“The ultimate goal of my research is to slow down or cure neurodegenerative diseases with early treatment interventions, and I can’t think of a better place to continue my work than Cleveland Clinic Nevada,” said Decourt. “I am enthused by Dr. Sabbagh and the entire Cleveland Clinic team’s proactive approach to the research of neurodegenerative disease and look forward to working alongside them in pursuit of new treatment options for those suffering from these debilitating diseases.”

For additional information about Cleveland Clinic Nevada, visit ClevelandClinic.org/Nevada.